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Abstract
Atopic dermatitis (AD) is an itchy chronic relapsing inflammatory skin
condition mostly affecting children than adults. Eczematous conditions are com-
mon worldwide with increase in the prevalence in both developed and developing
countries. AD in adults is of two types – the first type starts as AD in childhood and
gradually progresses to adulthood (Persistent AD) and the second type results from
AD developing in adulthood (Adult-onset AD). The article reviews and discusses
this condition in adults considering the epidemiology, risk factors, pathogenesis,
diagnostic criteria, and management of this condition.
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1. Introduction
Atopic dermatitis (AD) is an itchy chronic relapsing inflammatory skin condi-
tion mostly affecting children than adults with atopy. Atopy was derived from the
Greek word “atopos” by Coca and Cooke in 1923 for the grouping of asthma, hay
fever and asthma. [1] In an article by Kanwar, atopic dermatitis (AD) or atopic
eczema was defined as “an itchy, inflammatory skin condition characterized by
poorly defined erythema with edema, vesicles, and weeping in the acute stage and
skin thickening (lichenification) in the chronic stage,” [2] and in the year 2000,
Bannister and Freeman originated the term adult-onset atopic dermatitis for the
condition in adulthood. [3] AD usually occur as a continuum of childhood AD but
few cases start in adulthood, hence, the term - Adult onset AD. AD in adults is of
two types – the first type occurs as AD in childhood and progresses to adulthood
condition (Persistent AD) while the second type results from AD developing in
adulthood (Adult-onset AD). Eczema in adults usually runs a prolong course
impairing quality of life, relationships and sex life, and occupation. [4]
Atopy refers to “the genetic tendency to develop allergic diseases such as allergic
rhinitis, asthma and atopic dermatitis (eczema). Atopy is typically associated with
heightened immune responses to common allergens, especially inhaled allergens
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and food allergens.” [5] Rang et al. defined atopy as ‘a familial hypersensitivity of
the skin and the mucosa to environmental substances, associated with increased
production of immunoglobulin E (IgE) or altered pharmacologic reactivity.’ [6] The
ETFAD/EADV Eczema task force consensus 2020 defines atopy as the ‘familial
tendency to develop Th2 responses against common environmental antigens. [7]
The definition by ETFAD/EADV encompasses both subtypes of atopy – the
extrinsic (IgE-associated) subtype, and the intrinsic (non-IgE-associated) subtype.
Most AD affected persons have atopic diathesis. The Japanese Dermatological
Association defines atopic diathesis as: (1) Personal or family history (asthma,
allergic rhinitis and/or conjunctivitis, and atopic dermatitis), and/or (2) Predispo-
sition to overproduction of immunoglobulin E (IgE) antibodies. [8] The Japanese
Dermatological Association criteria is based on three clinical features that must be
present for diagnosis of AD: (1) pruritus, (2) exanthematous features and their
distribution, and (3) chronically relapsing course.
2. Etiology
The increasing number of adult AD cases in recent years has elicited interest in
determining factors causing and modifying the disease in adults. Susceptibility to
AD is attributable to both genetic and environmental causes. [9] The study by
Thomsen et al., showed that AD susceptibility and incidence are mainly due to
genetics with 82% cases of AD associated with genes and 18% associated with
nonshared environmental factors. [9] A monozyotic twin of an affected person has
a sevenfold risk of developing AD compared with a threefold increased risk in
dizygotic twin. [9]
Intrinsic IgE-mediated allergic inflammation may play an important role in the
pathobiology of elderly AD, similar to other age groups of AD. [10] About 5–15% of
cases have intrinsic non-IgE-allergic eczema. [4] Most of the adult AD patients have
sensitivity to aeroallergens such as cat epithet, dog epithel and housedusthouse dust
mites [11] while common food allergies affect only few. [4] There is a high inci-
dence of contact sensitization to environmental allergens such as nickel (in metals),
thiomersal (in eyedrops), fragrance mix (in cosmetics) and lanalcolum (in cos-
metics) in adult AD. [11] An increased occurrence of occupational allergic and
irritant contact dermatitis among adult AD cases have also been observed. [4]
Immunoglobulin E-mediated tests, atopy patch tests (APT), epicutaneous tests
(ET), in vitro allergy and Prick tests are usually positive on contact with environ-
mental allergens and to aero allergens. [11]. Pollens are associated with seasonal
relapse of AD.
There is specific immediate and delayed sensibilization to Malassezia
sympodialis in both intrinsic and extrinsic AD in adults. High rates of sensitization
to Dermatophagoides farinae and/or Dermatophagoides pteronyssinus have been
documented in patients with extrinsic allergy. House door mite (HDM) refers to a
large number of dust dwelling mites including the American HDM,
Dermatophagoides farinae Hughes, and the European HDM, Dermatophagoides
pteronyssinus. HDM is a common household aeroallergen known to cause asthma,
allergic rhinitis and AD. The indoor level of HDM is associated with the severity of
skin lesions. [12]
The proportion of contact sensitization to environmental allergens in the 34
adult atopic patients was remarkable (14 of 34, 41%). Out of the verified contact
allergens, nickel, fragrance mix, thimerosal and lanalcolum proved to be relevant.
House dust mite and cat epithel proved to be the most common relevant
aeroallergens. D. pteronyssinus and D. farinae sensibilization was high, particularly
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in patients with severe skin symptoms on the face, eyelids and hands. Pollens
should be considered in patients with seasonal relapse of AD. Sensitization to animal
epithel was usually indicated by the flare-up of skin symptoms upon contact with
animals. The relevance of the eliciting effects of sensitization could easily be
supported in most cases by the medical history and the distribution of skin symp-
toms. In some adult AD patients with long-lasting AD, the relevance of triggering
factors is hard to determine.
The intrinsic (non-IgE-allergic) eczema subtype affects 5–15% of cases. Classical
food allergy has a low importance, although non-IgE-mediated and pseudoallergic
reactions can cause eczema. Sensitivity to aeroallergens, especially dust mite, is
demonstrated in the majority of adult AD patients, including elderly adults, by
immunoglobulin E-mediated tests and/or atopy patch tests. Occupational allergic
and irritant contact dermatitis is increased. In adults, as in children, Staphylococcus
aureus colonization is very high, whereas adult skin is more heavily colonized with
Malassezia yeasts. Immediate and delayed sensitization to Malassezia sympodialis is
specific for intrinsic and extrinsic AD, occurring especially in head-and-neck
eczema. [4]
In the study by Pónyai et al., [11] atopy patch and epicutaneous tests (APT, ET),
which were supplemented by in vitro allergy and Prick tests – sensibilization was
evaluated by the comparison of in vivo and in vitro test results, medical history and
skin symptoms. The incidence of contact sensitization to environmental allergens
was remarkable: 13 of the EG, 1 of the IG (14 of 34, 41%) The allergens causing
positivity were nickel (6 of 13), thiomersal (3 of 13), mercury-amidochlorate (3 of
13), mercury-chloride (2 of 13), iodine chlorhyrdoxyquin (1 of 13), lanalcolum (1 of
13) and fragrance mix (1 of 13). Among the detected allergens, the following were
relevant: lanalcolum (1 of 13: cosmetics), fragrance mix (1 of 13: cosmetics), nickel
(1 of 13: metal objects), thiomersal (1 of 13: eyedrops).
3. Epidemiology
Atopic dermatitis often develops in infancy with about 75% occurring at less than
6 months and 90% before 5 years with about 60–70% resolving in the early teenage
years. [1] AD is manly a disease of children with prevalence of 10–20% in children in
developed countries. [13] A prevalent rate of 6% was found among children by
Oninla et al. [14] at a dermatology centre while Ayanlowo et al. [15] documented a
prevalence of 15% at another dermatology centre in Nigeria, a developing country.
Adult AD prevalence is 1–3% of adults world-wide. [4] Approximately 40% of
childhood AD persist till adulthood. [16] Adult-onset AD was reported by 1 out of 4
adults with AD. [17] Variable age of onset of adult AD from 18 to 71 years has been
reported. [2] About 9% of the cases seen at a contact dermatitis clinic had AD with
first onset at 20 years and above while an additional 8% had both adult-onset AD
and contact dermatitis. [18] An incidence rate of 18% was reported among adults
presenting at a contact dermatitis clinic in a study by the Postgraduate Institute of
Medical Education and Research (PGIMER), Chandigarh. A female preponderance
was found in adult AD in some studies though no gender predilection was reported
in children. [16, 18]
4. Risk factors
Atopic dermatitis runs a chronic course with acute exacerbations due to triggers
such as exposure to allergens (commonly pollens), skin irritants (for example
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woolen fabrics, exfoliating soaps, and detergents), stress conditions, skin dryness,
dry weather conditions, skin infections and food such as peanuts, gluten, eggs, soy,
dairy products and alcohol. [17] Persistence of atopic dermatitis till adulthood was
associated with early onset AD, childhood allergic rhinitis, hand eczema, allergic
contact dermatitis and increased specific IgE to Malassezia furfur. [19]
5. Pathogenesis
Various studies reported AD as a disease resulting from a complex interplay of
genetic factors, immunologic mechanisms, biochemical factors, environmental
triggers, and pharmacologic factors. [20–24] Sehra et al., [24] described the patho-
genesis of this disease and stated that it should translate to treatment strategies. In
the review by Leung, [20] AD was initially considered as a disease mediated by a
bone-marrow derived cell. This was based on the report that a bone marrow trans-
plant from an AD donor in positive immediate skin tests and symptoms of atopy in
the recipient. Also, patients with primary T cell immunodeficiency disorders were
found to have elevated serum IgE levels, eosinophilia, and skin lesions of AD.
Recently, Leung along with other researchers’ reported that AD occurs as a complex
interplay of immunologic, microbial, and epithelial interactions. [25]
Recent evidence also revealed that the underlying pathogenesis of AD has
shifted from focusing primarily on generalized immune system abnormalities in
Th1/Th2 cells to a complex interplay between primary epithelial barrier defect in
skin membrane (possibly a genetic defect) and dysregulation of immunological
mechanisms involving specific signaling pathways. [25, 26] These abnormalities
lead to membrane barrier defects resulting in increased transepidermal water loss
(TEWL) and increased allergen exposure as well as immunologic alteration toward
atopy. [27]
The exact pathogenesis remains unclear and the underlying mechanism that is
well known in the disease development and progression has been atopy. Children
with early onset AD often develop allergies to common environmental or food
allergens or infective agent [28] with positive skin prick test (SPT) or elevated
antigen-specific serum immunoglobulin E (IgE). This type of AD where specific IgE
plays a central role in AD is known as Extrinsic AD. The severity of AD has been
found to correlate directly with the number of SPT and/or levels of antigen-specific
IgE. [29] Extrinsic form accounts for about 45–75% of AD cases. [24]
Although total Ig E elevation is mostly seen in many AD individuals, other
factors also modulate the pathophysiology of AD giving rise to the non-atopic or
non-T-2 inflammation form of the disease. These are: genetic factors, age, gender,
maternal history of atopy, [24] ethnicity, [30] socioeconomic status, [31] environ-
mental factors, and early daycare attendance. [24] The intrinsic form might also
affect as many as two thirds of AD individuals. [32]
5.1 Pathogenic mechanisms
5.1.1 Epidermal barrier dysfunction
A strong family history has been reported in 40–60% of AD patients with
filaggrin (FLG) null mutation in 20–30%. [33, 34] Genetic mutations involving the
epidermal differentiation complex (EDC) gene on chromosome 1q21 impairs epi-
dermal differentiation resulting in stratum corneum barrier dysfunction. [35] The
nonsense mutations occur in the EDC gene encoding FLG which is also implicated
in asthma associated with AD. [36–38] The gene codes for profilaggrin, a large
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precursor protein molecule which is subsequently hydrolyzed to ten to twelve units
of FLG. [39]
Palmer et al., reported two independent loss-of-function genetic variants -
R510X and 2282del4 - mutations of the skin barrier gene encoding filaggrin (FLG)
as very strong predisposing factors. [38] FLG, a filament aggregating protein, binds
keratin intermediate fibers to the envelope of the stratum corneum cells and facili-
tates terminal differentiation of the epidermis. [38] Therefore, filaggrin is needed
for the formation of skin barrier to maintain hydration and provide protection from
environmental insults and infective agents. [40, 41] Recent studies have linked
genetic FLG mutations to Th2 mediated AD and not non-Th2 inflammation AD
giving rise to suggestions that skin barrier defect underlies the development of
secondary allergic symptoms and respiratory atopy. [24] The degree of membrane
disruption directly correlates with the severity of AD. [42]
The study by Pellerin et al. showed that the stratum corneum of lesional skin as
well as the clinically nonlesional skin of adults AD patients has reduced expression of
FLG and FLG-like proteins. [43] This was found to be as a result of nonsense muta-
tions, proinflammatory cytokines and some defects in the proFLG processing. The
study concluded that skin inflammation contributing to the AD-related epidermal
barrier dysfunction is by downregulation of FLG and FLG-like proteins. FLGmutation
has been identified as themost common genetic factor associated with AD and present
in 15–50%. [44] However, 40% of FLG mutant gene carrier do not have AD. [38]
The epithelium inAD also have decreased barrier-stabilizing proteins such as loricrin
(LOR), involucrin (IVL), and proline rich particles. [44] Tumor necrosis factor-alpha
and interleukin (IL)-4 result in downregulation of LOR and filaggrin (FLG). [29, 45] In
AD lesional skin, lipid synthesis is reduced [46] due to increased expression of enzyme
stearoyl-CoA desaturase leading to increased unsaturated fatty acids and abnormal
keratinization. [47] Th2 cytokines and IFN-γ also reduces long-chain free fatty acids
(FFA) and ester linked-hydroxy (EO) ceramides in the skinmembrane. [48, 49]
Many researchers have reported that defective skin barrier particularly in the
epidermis preludes the pathologies seen in AD development mainly in the following
ways: [26, 50–52].
• Defects in epidermal proteins such as FLG, keratins, transglutaminases, loricrin,
involucrin reduces skin hydration and inflammatory thresholds while increasing
skin pH, inflammatory cytokines, and allergen and microbes permeability. [26]
• Reduction in claudins increases transepidermal water loss (TEWL), reduces
hydration, and allows allergens and microorganisms invasion. [53]
• Decreased long-chain FFA and ceramides increases TEWL and infections. [26]
• Decreased cathelicidin and human β-defensins increase microbial infections
(mostly Staph. aureus) and pro-inflammatory cytokines. [26]
5.1.2 Immune system dysregulation
Polymorphisms of genes in the Th2 signaling pathway particularly cytokine
receptors (IL-4R and IL-13R) are associated with immune dysfunction in AD. [54–57]
Also implicated are genes transcribing for IL-31 and IL-33, thymic stromal
lymphopoietin (TSLP) and its receptors (IL-7R and TSLPR), interferon regulatory
factor 2, signal transducer and activator of transcription (STAT) 6, Toll-like receptor
2, and high-affinity IgE receptor (FcRI), [26, 54, 56, 58–60] vitamin D receptor and
cytochrome P450 (CYP27A1 variant involved in D3 metabolism). [61, 62] Environ-
mental factors (mostly allergens, microorganisms, smoke, and chemical irritants) also
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cause modifications in DNA resulting in epidermal and genetic changes (epigenetic
changes) without changing the DNA sequence of the corneocytes. [56]
Of recent, the skin epithelium was found to produce IL-25, IL-33, and/or TSLP
(in response to extracellular molecules such as parasites and allergens) which acti-
vates skin group 2 innate lymphoid cells (ILC2). ILC2 produces IL-5, IL-9 and IL-13
which are Type 2 cytokines. [63] The TH2 cytokines (IL-4, IL-13, IL-31) and TH22
cytokine (IL-22) are believed to play roles in the overall pathogenesis of atopic
dermatitis but mostly acute AD (Figure 1). [64–66]
Figure 1.
Pathogenesis of atopic dermatitis. Damage to the skin barrier allows penetration of the skin by allergens,
environmental factors and infective organisms activating the skin antigen-presenting cells (APCs). The APCs migrate
to lymph nodes and stimulate naive T cells differentiation into TH2 cells and B lymphocytes. Damaged epithelial cells
releases TSLP,TNF-α and IFN-γ and other TH2 cytokines (mostly IL-25 and IL-33) which induces mostly TH2
inflammation and subsequently keratinocyte apoptosis.TH2,T helper 2 cells; ILC2, innate lymphoid cell; TSLP,
thymic stromal lymphopoietin; TSLPR, thymic stromal lymphopoietin receptor. Cited from reference [100].
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IL-4 is primarily produced by mast cells, Th2 cells, oesinophils and basophils.
[67] IL-4 stimulates both the humoral and innate immunity. It reduces the expres-
sion epidermal differentiation complex (EDC) genes which regulates keratinocytes
function. It activates B cell production which ingests antigens and presents them as
major histocompatibility complex (MHC) II molecules to which T cells bind leading
to cytokine production and signals to other phagocytes. The T cells further stimu-
late these activated B cells and differentiation into plasma cells leading to antibody
production. IL-4 enhances the development of Th2 cells, suppresses the formation
of major terminal differentiation proteins by downregulating the encoding genes
for FLG, LOR, and IVL, increases fibronectin, and increases adhesion of S. aureus to
the skin. [64, 68–71]
IL-13 acts similarly to IL-4 and these two are the most frequently produced
cytokines by Th2 cells. IL-13 promotes tissue inflammation by inducing cellular
migration (CD4+ T-cells, mast cells, eosinophils, and macrophages) to the dermis.
[68, 71] Both IL-4 and IL-13 hinders keratinocyte differentiation resulting in mem-
brane barrier dysfunction and increase periostin expression stimulating skin
remodeling in chronic AD. [72, 73] They induce cytokines, epidermal dysfunction,
suppress antimicrobial peptides (AMP), and stimulates allergic nflammation.
[64, 74] Another study by Howell et al., [74] showed that filaggrin gene expression
by keratinocytes stimulated by IL-4 and IL-13 was significantly reduced when
compared with normal skin. [75]
IL-5 is produced by Th2, eosinophils and mast cells though eosinophils are the
primary IL-5Rα-expressing cells. It functions as an eosinophil colony-stimulating
factor, B-cells growth factor and increases immunoglobulin secretion – mostly IgA.
[68, 76] IL-31, a cytokine mainly produced by CD4+ Th2 cells is a potent mediator
of inflammation. [77] Monocytes, epithelial cells, and T cells have the receptor – IL-
31R, on their cell membrane. [77] IL-31R induces and potentiates pruritus in AD
[76, 78] by production of natriuretic peptide in the brain and chemokine release
from keratinocytes. [79]
According to Rebane et al., IFN-γ is the characteristic cytokine induced by Th1
cells. [80] In acute AD, immunoglobulin G (IgG) inhibits the production of IFN-γ.
[81] Interferon-gamma is secreted predominantly by activated lymphocytes such as
CD4 T helper type 1 (Th1) cells and CD8 cytotoxic T cells. [82] Other cells produc-
ing IFN-γ are natural killer (NK) cells, B cells and antigen-presenting cells (APCs) –
macrophages, and these cells aggregate in the skin during inflammatory reactions
and infections. [83] Werfel et al., reported that CD8 T cells are part of the early
cellular response in AD. [84] Higher CD8 IL-13+ 1CLA1 frequencies were seen in
adults compared with children with AD. [85] CD8 T cells constitute 15% of allergen-
specific T cells in the skin. [86] These cells stimulates the production of interferon-γ
(IFN-γ), IL-13, and IL-22. [87–89] It was also reported that IFN-γ upregulated 3
apoptosis-related genes (NOD2, DUSP1, and ADM) and stimulates the
overexpression of 8 genes (CCDC109B, CCL5, CCL8, IFI35, LYN, RAB31, IFITM1,
and IFITM2) in keratinocytes of lesional skin.
TH17-associatedmolecules (IL-17A, peptidase inhibitor 3/elafin, and CCL20) are
consistently upregulated in both patients with acute and chronic AD. IL-17 production
is higher in intrinsic AD, and severe AD. [90] It reduces FLG and INVwhile stimulating
antimicrobial peptide human beta-defensin 2 (HBD-2) in keratinocytes. [91, 92]
Apart from elevated IgE levels and eosinophilia, Leung reported that the
peripheral blood has the following immunologic responses: [20].
• Increased basophil spontaneous histamine release
• Decreased CD8 suppressor/cytotoxic number and function
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• Increased expression of CD23 on mononuclear cells
• Chronic macrophage activation, increased GM-CSF, prostaglandin E2, and
IL-10
• Expansion of IL-4– and IL-5–secreting Th2-type cells
• Decreased numbers of IFN-γ–secreting Th1-type cells
• Increased serum sIL-2 receptor levels
• Increased serum eosinophil cationic protein levels
• Increased soluble E-selectin levels
• Increased soluble vascular cell adhesion molecule-1 levels
• Increased soluble intercellular adhesion molecule-1 levels
These immunologic changes underlies the skin inflammatory process in AD.
The cellular and cytokines infiltrates in the skin depends on the duration of the
lesion. Cellular infiltrates particularly T cells occur as an immune response in AD
patients. T lymphocytes are moderately increased in the dermal layer of nonlesional
skin with marked increase in acutely inflamed areas and acute flares of chronic
lesions resulting in epidermal cell apoptosis and spongiosis. Nonlesional skin has no
eosinophils and macrophages, and cytokines seen are IL_4, IL-13 and IL_16 [20, 80]
In acute lesional skin, cellular infiltrates consists of mostly T-cells, moderate
amount of inflammatory dendritic cells (IDCs) mostly Langerhans cells, eosino-
phils, macrophages, IL-4, IL-13, IL-5, IL-22, IL-16, IL-31 and Granulocyte-
macrophage colony-stimulating factor (GM-CSF). (20). Chronic lesional skin has
mostly eosinophils and macrophages with moderate number of T cells, GM-CSF,
and cytokines type are IL-4/13, IL-5, IL-12, IL-16, IL-31 and Interferon-γ. (20).
a. Acute Dermatitis: According to Grittler, AD is currently considered a biphasic
disease depending on the type of cellular immune response to numerous
environmental antigens and infections. [64] An initial phase of acute disease
characterized by predominantly Th2 cells, as well as ThH22 and few
eosinophils progresses to a chronic disease and a switch to mostly Th1 cells,
and Th17 cells. Th2 lymphocytes are the most predominant cells in all AD
phenotypes, and play a key role in all allergic inflammation. [40, 93]
Infiltration by Th2 cells are more in the acute phase than other phenotypes.
These cells are targeted in immunotherapy for precision medicine. [94, 95]
b. Chronic Dermatitis: Allergen specific T-cell clone (TCC) from spontaneous
chronic lesional skin of AD patients was found different from the TCC
isolated from inhalant allergen patch test lesions. [86] These TCC are
allergen-nonspecific cells that produce IFN-γ and the chronic changes seen in
the skin and were found to be Th1 cells. [84] Many other studies also reported
that Th1 cells increases in the lesions in chronic AD from an initial Th2
polarization. [96–98]
The Janus kinase-signal transducer and activator of transcription (JAK/STAT)
pathway acts downstream of more than 50 cytokines. [99] It is central to
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inflammatory processes involving B-cells, T-cells, neutrophils, macrophages and
natural killer cells. Inhibitors of this pathway reduce are anti-inflammatory.
5.2 AD clinical phenotypes
AD has variable phenotypes that vary with age of onset, race, clinical course
(acute or chronic), disease severity, therapeutic response, reactions to infectious
agents, and allergic/irritant substances, IgE reactivity, and presence of other allergic
diseases (asthma, allergic rhinitis, and food allergies). [94]
There are three main phenotypes of atopic dermatitis (Figure 2): (1) nonlesional
skin, (2) acute AD, and (3) chronic remitting relapsing AD with acute flares. The
underlying cellular and immune mechanisms in all three phenotypes are based on
dysfunctional immune response as well as epithelial disruption. It is believed that
underlying these complex clinical phenotypes are biomarkers that can be validated,
and qualified for precision medicine for individualized treatment of AD. [100]
(2) non–type 2 immune response AD - with Th1-, Th17-, and Th22-induced
inflammatory process and resultant epithelial dysfunction. [101–103]
5.3 Pathological markers
Disease assessment can be done pathologically. Biomarkers, such as CCL17, can be
used for assessment of AD severity while filaggrin deficiency is being considered as a
potential candidate for prognosticating the disease. Indoleamine 2,3-dioxygenase has
been found useful as a predictive marker for viral skin infections [104].
5.4 Triggers for AD onset and exacerbation
Triggers are predisposing factors to AD episodes or flares. The control of these
triggers are paramount in the treatment of AD. [105] and in improving the quality
of life by maintain a disease free periods for the affected individuals or patients.
Atopic dermatitis may be triggered by microbial agents (common cold, second-
ary infection of lesions and skin infections), food (commonly due to eggs, milk,
peanuts, wheat, soy, tree nuts, and fish and other sea foods), [106] aeroallergens
(mostly house dust mites, molds, pollens, cigarette smoke, and animal dander),
cosmetics, fragrances, weather (extremes of temperature and sweating), [106, 107]
clothing such as wool [108], irritants, and sex hormones. [109] The two types of
allergic reactions that can result from these triggers are – (1) Immediate allergic
Figure 2.
Proposed atopic dermatitis Endotypes. Adapted from reference [100].
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reactions: IgE mediated type III with activation of the complement system, and (2)
Delayed allergic reactions: due to activation of T lymphocytes and eosinophils. [110]
A. Microbial agents.
Dysfunctional adaptive immune response resulting in increased total and spe-
cific IgE levels, [111, 112] and innate immune system abnormalities such as
reduced chemotaxis of cells to skin and antimicrobial peptide levels, Toll-like
receptor defects [113] are the underlying factors contributing to skin infection
and colonization. Disruption of the epidermal barrier facilitates microbial
infection and colonization in AD patients. [114] The skin of AD individuals are
highly predisposed to colonization or infection by various organisms most
especially Staphylococcus aureus and Herpes simplex virus. [115]
The microbial organisms produce superantigens which stimulates marked
inflammation. S. aureus has been implicated as a trigger of AD and as a factor
responsible for chronic relapsing clinical course. [16] It releases toxins and
superantigens that stimulates the innate immune response leading to T cells and
macrophages production. It has been found in the skin of 80–100% AD indi-
viduals. [16] Specific IgE antibodies against staphylococcal enterotoxins
corresponding to severity of the disease have been found inmost AD cases. [16]
The stimulation of chemokines such as TH2 cytokines IL-4 and IL-13 leads to
reduced mobilization of human beta-defensin-2 (HBD-2) and impairs
keratinocytes clearing of Staph. aureus while their neutralization significantly
leads to clearance of the infective agent. [115–117] Apart from areas of infec-
tion, S aureus also colonizes normal-appearing skin in AD patients. [117]
Viral skin infections occur in AD patients more than other individuals with-
out atopy. These infections may be localized or widespread. The most fre-
quently seen viral infections are herpes simplex, warts and molluscum
contagiosum. According to Damour et al., susceptibility is increased by
overexpression of Th2 cytokines - IL-4, IL-13, IL-25, IL-33, and TSLP, low the
AMP cathelicidin LL-37 and HBD-2 production; reduced IFN-γ, defect in
cellular immune response by NK cells and dendritic cells. [115]
HSV may present as umbilicated vesicles, punched out erosions, impetigo-like
lesions or secondarily infect atopic skin lesions. [115] Tzanck smear, PCR and
viral culture can be used to confirm diagnosis. Also, fungi infection particularly
Malassezia sympodialis has been found to contribute to chronic inflammation in
AD, and it is associated with specific IgE antibodies againstM. sympodialis. It
was found to be more common in patients with head and neck type of AD.
B. Aeroallergens.
Aeroallergens are one of themost common environmental allergens causing AD
flares or worsening. Many AD individuals have been found to have delayed
hypersensitivity reactions to aeroallergens identified in their environment or
reported by the patients while they have no reactions to aeroallergens which
they had not been exposed to. Aeroallergens often producing delayed reactions
with patch tests in adults AD are house dust mite, pollens (weed, grass and
tree), and danders. [118] Adults with IgE sensitization to these aeroallergens
have increased risk of developing persistent lesions of AD and other allergic
diseases. [119] Control measures such as the use of allergen-impermeable mat-
tress encasing, acaridae spray containing tannic acid and benzylbenzoate has
been found to reduce the house dust mite antigen, Der p1. [120]
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C. Food allergens.
Food allergy refers to an adverse immune-mediated reaction to ingested food
product which is reproducible. [121, 122] Food intolerance is an undesirable
non-allergic food reactions that does not involve the immune system (lactose
intolerance). Prevalence of FA in adults is about 1–2%. [122] Some double-
blind placebo-controlled oral food challenges (DBPCFCs) have shown that FA
in adults AD are considerably lesser than in children, may not correlate with
skin prick testing (SPT) or patch testing, and there may be little benefit to
elimination diets. [123] However, a significant association has been reported
between the IgE-mediated food allergy and severity of AD in adults. [124]
The immune reactions are of three types: [122].
a. IgE-mediated (immediate hypersensitivity reaction) - serum specific IgE
antibody present with specific symptoms on ingestion of the food allergen
within 2 hours. Symptoms include:
i. Skin symptoms – itching of lips and/or eyes, eye redness, swelling of lips/
tongue, urticaria, angioedema, flushing, rash, exacerbation of eczema;
ii. Gastrointestinal symptoms – nausea, vomiting, diarrhea, pain and
bloating;
iii. Respiratory symptoms – nasal itching, rhinorrhea, sneezing,
wheezing, dyspnea, or anaphylaxis;
b. Non-IgE-mediated (T-cell mediated with histological changes); (c)
Combined reactions.
The skin is affected in 86% of food allergies and 38% respiratory system involve-
ment. [121] The “priority antigens”which constitutes >90% of FA are dairy products,
eggs (chicken), nuts (e.g., hazelnuts, walnuts, almonds, cashews, peanuts), soy
beans, fish, crustaceans and shellfish, gluten foods (e.g., wheat, rye, barley), sesame
and mustard. [121, 125] Less commonly: legumes, some fruits/juices (e.g., apple,
grape), and vegetables (e.g., onions celery, carrots). [125] It is thought that raw food
ingestion and food borne microbes may act as antigen. [126] This elicits immune
responses by binding to immature gut villus, by increasing gut permeability, and by
antigen transfer. [126] Food antigens produce anaphylactic reactions in sensitized
individuals due to loss of oral tolerance to these antigens. [127].
Current therapies for FA entails strict avoidance of the offending food and aller-
gen immunotherapy (AIT) - oral immunotherapy (OIT), sublingual immunotherapy
(SLIT) and epicutaneous immunotherapy (EPIT) to ensure clinical desensitization,
sustained unresponsiveness to allergens, and oral tolerance. [127] SLIT and EPIT are
safer and more tolerable than OIT due to lesser ingestion of protein. [128]
6. Clinical features
6.1 Clinical symptoms and signs
Adult AD presentations are variable and differs by age, severity and course of
the disease (acute or chronic course). It is a relapsing and remitting condition, with
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episodes of disease exacerbation that occurs as frequently as two or three times per
month. [13] Clinical symptoms and signs of adult/adolescent AD as reported by Liu
et al., [129] in a multicenter study (42 dermatological centers) of 1605 AD cases
over 12 years old (in decreasing percentages) are:
Pruritus (98.6), Xerosis (74.1), Associated environmental/emotional factors
(73.9), Personal or family history of atopic diseases (61.4), Itching upon sweating
(56.0), Flexural dermatitis (52.0), Facial pallor/facial erythema (35.5), Intolerance
to wool (30.2), Eczema/AD before 12 years old (29.5), Scalp eczema/pityriasis
(28.8), Urticaria/angioedema (26.8), Periauricular fissuring/eczema (25.8), Hand
and/or foot dermatitis (24.7), Ichthyosis/palmar hyperlinearity/keratosis pilaris
(23.3), Eyelid eczema (20.8), Eczema/AD history before 2 years old (20.2),
Perifollicular accentuation (19.5), White dermographism (19.0), Nummular
eczema (18.4), Pompholyx of hand/foot (17.2), Liable to skin infections (16.8),
Anterior neck folds (16.7), Cheilitis (15.0), Perineum eczema (14.3), Orbital dark-
ening (11.4), Pityriasis alba (9.5), Breast eczema (7.9), Recurrent conjunctivitis
(7.3), Dennie–Morgan infraorbital fold (6.1), Anterior subcapsular cataracts (3.4),
Keratoconus (1.3).
The characteristic sites of distribution of skin symptoms for adult AD are the
hands, shoulders, neck, flexures, face and eyelids. The extremities and the trunk
were less involved. [11] Adult AD characteristically presents as lichenified eczema
on both extensor and flexural surfaces of the flexures, face, neck, shoulders and
hands. In elderly adults, eczematous erythroderma is common. [4] Pruritus is a
major symptom and major criteria in AD. It increases in the night.
6.2 Clinical patterns of adult AD




Some classify the clinical features into (a) adult-onset AD, and (b) persistent AD
and AD with relapsing course grouped together as persistent/recurring infantile or
childhood AD. [131] In the elderly, AD can occur as geriatric onset AD, geriatric
recurrence of typical childhood AD, and geriatric recurrence and /or continuation
of adult AD. [10]
Persistent AD – refers to childhood AD running a chronic recurrent course up to
and even in adulthood; occurs in 20–30% childhood cases. [131] Presentations are
similar to children with flexural involvement (flexor surface of extremities) in
majority of patients with pre-adult-onset. [132] The flexures are the areas initially
involved. The flexor surface of arms and legs are also more highly involved than
other body areas in these patients than those with adult-onset adult AD. [132]
Affected cases usually have diffuse, lichenified, symmetrical lesions in the flexures
mostly with facial eczema, dirty neck, and variable involvement of hands, limbs
and trunk. Dirty neck, and vitiligo-like lichenified lesions in the flexures are signs of
chronicity. [133–135]
Relapsing AD – this refers to childhood AD with complete resolution before or
during adolescence, and recurrence in adulthood; occurs in about 12.2% cases of
childhood AD. [131] Adult AD cases are prone to contact hand eczema while fewwith
contact eczema have AD. According to Salvador et al., many of these patients have
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chronic hand eczema as a result of atopy precipitated by irritant substances (heat,
dust, soaps, etc) at work places or jobs causing wet hands. [131] This is often confused
with contact irritant dermatitis and it is difficult to distinguish the two. [131, 136–138]
Adult-onset AD – In a study by Son et al., the body-site distribution of areas
initially involved showed that the head and neck areas are the sites initially affected
at the onset in adult-onset AD in contrast to flexural areas in pre-adult-onset AD.
[132] The trunk was the most common area affected while flexural surfaces of arms
and legs are the most affected area in persistent AD. [132]
From the study by Tanei et al., the senile-type AD usually have involvement of
the face and neck, trunk, lichenification in flexural and extensor surfaces of arms
and legs. [139] The antecubital and popliteal surfaces are less affected. Cases with
moderate to severe eczema have other features of AD: erythroderma particularly on
the face (atopic red face), loss of lateral eyebrows (Hertoghe sign), facial pallor,
dirty neck (eczema with reticulate, ripple, or poikilodermic pigmentation), goose
skin and Dennie–Morgan infraorbital folds. [139]
Tanei [140], described 3 types of lichenification in the antecubital areas of
elderly patients with AD:
a. Localized lichenified eczema in the elbow fold;
b. Diffuse lichenified eczema in the elbow fold and flexure site of the arm;
c. Lichenified eczema around the scarcely involved elbow fold (reverse sign).
In the elderly, the classical type of localized lichenified eczema at elbow and knee
folds is less common than the reverse type where lesions are around unaffected folds.
6.3 Clinical assessment of AD in adults
Assessment of AD should be done to determine the appropriate treatment as
well as monitor response to therapy. SCORAD – SCORing Atopic Dermatitis – is a
clinical tool for assessing the severity (extent/spread, intensity, and symptoms) of
atopic dermatitis both objectively and subjectively. [141, 142] It was developed in
1993 by the European Task Force on Atopic Dermatitis to provide a consensus
approach to AD management and useful in both children and adults. [143] Intensity
of the symptoms was giving a weight of 60% and 20% each was allocated to spread
(extent) and subjective signs (insomnia, itch). [144]
It consists of 3 components – A (Area or Extent), B (Intensity), C (Subjective
symptoms). The formula for obtaining the total AD score of an individual is A/5 + 7B/
2 + C. Area is expressed as a percentage of the whole body using the rule of 9 with a
maximum value of 100%. Intensity has a maximum of 18 from a score of 6 for each of
redness, swelling, oozing/crusting, scratch marks, skin thickening (lichenification),
and dryness (assessed in an area where there is no inflammation). Subjective symp-
toms are itch or sleeplessness assessed on a scale of 0–10 for each with a maximum 20.
7. Diagnostic criteria
Reports of AD in adults are not common and the clinical features are not cate-
gorical. However, the diagnosis of atopic dermatitis (AD) is based on its clinical
symptoms regardless of age or sex of the individual. According to Tada [8], in the
review of AD diagnostic criteria, the first concept of AD was described and
published in 1933 by Wise and Sulzberger. [145]
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The first diagnostic criteria published was in 1961 by Rajka. [8] Both Hanifin and
Rajka modified and combined their criteria in 1980 to form the most commonly
used criteria (Table 1), [146] and many dermatological societies have also devel-
oped their criteria for this condition. According to Tada, the diagnostic standard by
Hanifin and Rajka is useful in AD diagnosis in children and it also remains useful in
adults as well. It has 6 major and 23 minor criteria.
According to the UK Working Party on AD in childhood, to qualify as a case of
atopic dermatitis, the individual must have an itchy skin condition plus three or
more of the following: history of flexural involvement, a history of asthma/hay
fever, a history of a generalized dry skin, onset of rash under the age of 2 years, or
visible flexural dermatitis. This has a sensitivity of 85% and specificity of 96%. [147]






• Ocular complication (keratoconus, cataract and/or retinal detachment)
• Kaposi’s varicelliform eruption
9. Differential diagnoses
Differentials of adult-onset AD are seborrheic dermatitis, allergic contact dermati-
tis, cutaneous T-cell lymphoma, polymorphous light eruption, actinic prurigo, and
Major criteria (3 or more needed for diagnosis):
1. Pruritus
2.Typical morphology and distribution
3.Flexural lichenification in adults
4.Facial and extensor involvement in infants and children
5.Dermatitis - Chronically or chronically relapsing
6.Personal or family history of atopy (asthma, hay fever, atopic dermatitis)
Minor criteria (3 or more needed for diagnosis):
(1) Xerosis (2) Ichthyosis/palmar hyperlinearity, keratosis pilaris (3) Immediate (type I) skin test
reaction (4) Elevated serum IgE (5) Early age of onset (6) Tendency toward cutaneous infections
(especially staph. Aureus and herpes simplex), impaired cell mediated immunity (7) Tendency toward
non-specific hand or foot dermatitis (8) Nipple eczema (9) Cheilitis (10) Recurrent conjunctivitis (11)
Dennie-Morgan infraorbital fold (12) Keratoconus (13) Anterior subcapsular cataracts (14) Orbital
darkening (15) Facial pallor, facial erythema (16) Pityriasis alba (17) Anterior neck folds (18) Itch
when sweating (19) Intolereance to wool ad lipid solvents (20) Periofollicular accentuation (21) Food
intolerance (22) Course influenced by environmental and emotional factors (23) White
dermographism, delayed blanch
Table 1.
Hanifin and Rajka diagnostic criteria for atopic dermatitis.
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psoriasis, prurigo simplex, scabies,miliaria, ichthyosis, xerotic eczema, hand dermatitis
(non-atopic), psoriasis, immunodeficiency diseases, collagen diseases (SLE, dermato-
myositis), Netherton syndrome. In children, scabies, tinea corporis, seborrheic derma-
titis, nutritional deficiency and allergic contact dermatitis are close differentials. [148]
10. Investigations
Investigations for AD are rarely required. Most investigations are carried out to
identify triggering factors where applicable. A skin prick test is used for food and
aeroallergen sensitization. Extracts or fresh food, and aeroallergens can be tested by
placing them directly on the skin, which is then pricked through the liquid. This can
also apply for local foods, which can be crushed with saline and similarly tested. The
‘prick-prick test’ can also be used by pricking the food with a lancet and then pricking
the skin. The test site is observed in 15–20 minutes and the wheal reaction measured
and recorded. A positive control with histamine should be ≥3 mm and a negative
control is done with normal saline. [149] Patch tests are performed to diagnose
allergic contact dermatitis (ACD); or a worsening dermatitis as a result of ACD to a
constituent of the topical treatment. [150] Patch test is done for superimposed allergic
contact dermatitis; in cases of suspected hand dermatitis. The highly specific atopy
patch test is used to diagnose type IV hypersensitivity reactions.
Skin biopsy is usually required when there is erythroderma and a need to identify
the underlying etiology. Histological findings can be suggestive of AD; however, they
are not reliable for making a diagnosis. Total serum IgE levels are not specific for AD
and does not correlate with disease severity. It is elevated in 50% of cases of AD.
In adult AD, colonization with Staphylococcus aureus is high and adult skin is
more heavily colonized with Malassezia yeasts. [4] A positive ImmunoCAP assay
for Malassezia species may be carried out. [149] This can then be treated with
appropriate oral therapy. Swab tests can be carried out where necessary for sec-
ondary bacterial infections. Other tests are carried out appropriately based on other
associated findings from the history or clinical examination.
11. Management
A very important part of management of AD is the education and counseling of all
AD patients. With good understanding of the disease and what aggravates it, disease
control can be achieved with the right skin care plan and an understanding of how to
manage the flares. Successful management requires identification, elimination and
prevention of specific identifiable and non-identifiable trigger factors. Managing AD
requires a multispecialty approach which involves the dermatologist, allergologist,
psychologist and nutritionist. Treatment regimens are usually based on the severity of
the condition (Table 2). Evaluation and treatment according to ETFAD/EADV
Eczema task force 2020 consensus paper is useful in routine clinical practice for AD
in adults. [7] Patients should be educated on all available therapeutic options and they
must actively participate in choosing the best option for themselves and their cir-
cumstance. Treatment regimens should be discussed and explained to individuals and
their families to ensure adherence and compliance. Expectations, limitations, thera-
peutic options and prognosis are key to the overall management of AD.
Topical treatment.
The use of emollients is required both during an acute phase and as maintenance
therapy as it forms the cornerstone of treatment for all types and severity of AD.
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Therapeutic baths in salt-rich water, colloidal oatmeal, wet –wrap dressings and
topical antibiotics play an important role in this part of AD treatment.
Topical corticosteroids (TCS) are mainly used during a flare (Table 3). There
are various potencies and dosages which are used based on severity of AD. TCS are
used in active disease for up to 4 weeks and then 2 to 3 times weekly for preventive
treatment. Topical calcineurin inhibitors (TCIs) are recommended for mainte-
nance. Tacrolimus is more effective than pimecrolimus, and has been shown to be
effective and well tolerated. [150–152] TCIs suppresses calcineurin which stimulates
the expression of interleukin 2 (IL-2), a cytokine that regulates the T cell response.
TCIs inhibit mast cell and neutrophil activation, basophil, eosinophil, and
Langerhans cells functions.
Crisaborole, a topical phosphodiesterase-4 (PDE-4) inhibitor which
downregulates the T-cell signaling pathways by inhibiting cAMP degradation is
effective in reducing skin inflammation. [153]
Other forms of topical therapy include therapeutic baths in salt-rich water or
colloidal oatmeal; diluted bleach baths and wet –wrap dressings and topical antibi-
otic when required.
Phototherapy can be used for moderate to severe AD, particularly where topical
therapy has failed. Narrow band UVB in combination with medium dose UVA is
Severity Eruption TCS application
Severe Primarily severe swelling/ edema /infiltration
or erythema with lichenification, multiple
papules, severe scales, crusts, vesicles,
erosion, multiple excoriations and
pruriginous nodules
Use of very strong or strong rank TCS is the
first-line treatment. Strongest rank TCS are
also available for refractory pruriginous
nodules if sufficient effects are not
achieved by applying very strong rank TCS
Moderate Primarily moderate erythema, scales, a few
papules and excoriations
Use of strong or medium rank TCS is the
first-line treatment
Mild Primarily dryness, mild erythema and scales Use of strong or medium rank TCS is the
first-line treatment
Slight Primarily dryness with negligible
inflammation
Topical application of medicines other than
TCS (emollients)
Table 3.
Severity of eruption and topical corticosteroid (TCS) application. TCS, topical corticosteroid. [cited from
Japanese guidelines for atopic dermatitis 2020. https://doi.org/10.1016/j.alit.2020.02.006, an open access




Educate patients Mildly potent TCS Moderately potent TCS Potent TCS
Emollients TCIs Crisaborole Short course: OCS
Bath oils Crisaborole Wet wrap therapy Short course: Cyclosporine A
Avoid triggers NB-UVB/PUVA1 Biologics: Dupilumab
Antihistamines
(Sedating type)




The treatment recommendations according to severity in adult AD.
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effective. [154–156] This mode of treatment however does have long term adverse
effects (skin malignancies), and may not be available in all settings.
Systemic treatment (Dosages and side effects cited from Megna et al.) [157].
AD is being recognized as a systemic disease with atopic and nonatopic
comorbidities. This plays an important role in the subsequent management and
therapeutic implications for this condition.
Systemic therapy is required for chronic, severe cases, resistant cases, and when
topical therapy has failed to control the disease. These include antihistamines, oral
corticosteroids, immunosuppressive drugs and biologics. Combination of both top-
ical and systemic is indicated for severe and resistant cases. [157]
Antihistamines may help to reduce itching. [158] Hydroxyzine and diphenhy-
dramine hydrochloride provide a certain degree of relief but are not effective
without other treatments.
Erythromycin, clarithromycin or cephalosporins can be used for 7–10 days for
widespread bacterial skin infections. They are not recommended for use where
there is no evidence of clinical infection as staphylococcal organisms are known to
colonize the skin of AD patients. Systemic antifungals - itraconazole and ketocona-
zole – useful for cases with Malassezia sympodialis infection. [159]
1.Non-biologic drugs (Immunosuppressant and other)
a. Oral corticosteroids (OCS) are effective for short term treatment for
acute flares (Table 2) OCS rapidly improve the clinical symptoms of AD
and are best used for short courses up to 1 week. [157] Long term use of
oral steroids is not recommended because of the well-known side effects
associated with them. These include hypertension, gastric ulcers,
osteoporosis, diabetes and Cushing syndrome; as well as a rebound flare
which can occur when they are abruptly stopped. They should be tapered
to avoid relapse and rebound of AD. [157, 159–161] Dosage: Varies with
type, AD severity, and comorbidities). Important Side effects: Diabetes,
hypertension, skin atrophy, gastric ulcer, osteoporosis, glaucoma,
pigmentary changes on prolonged use, and Cushing syndrome.
b. Cyclosporine is the most widely used and first choice of systemic agents
for the control of AD not responding to topical therapy. It is an
immunomodulatory drug that inhibits interleukin by selective inhibition
of cytokine transcription in activated T lymphocyte. Those on
cyclosporine require close monitoring to avoid common side effects
(nephrotoxicity, tremors, hypertension, electrolyte imbalances, etc.).
Baseline tests and regular monitoring is required; particularly their renal
status. Cyclosporine remains the only approved drug for systemic
treatment of adult AD. Dosage: 2.5 to 5 mg/kg/day. Important Side
effects: Nephrotoxicity, Hypertension, nausea, diarrhea, headache,
paresthesia and myalgias.
c. Methotrexate is effective in the treatment for moderate to severe AD. AD
control be achieved with at a low dose for prolonged periods without any
significant risk to the patient. It is a relatively safe drug. [162] Dosage:
5–25 mg/week. Important Side effects: Liver dysfunction, gastrointestinal
complaints, hematological abnormalities, fatigue, and headache.
d. Azathioprine is a purine synthesis inhibitor that reduces leukocyte
proliferation. Various studies have been carried out with varying results.
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It is used off label in situations where cyclosporine is contraindicated, or
there has been no response. Dosage: 2–3 mg/kg twice a day. Important
Side effects: Gastrointestinal disturbances, liver dysfunction, and
leucopenia.
e. Others:
i. Mycophenolic mofetil (MMF) - Dosage: MMF:1000–2000 mg/
day; EC-MPA enteric-coated mychophenolate sodium: 1440 mg/
day. Side effects: Gastrointestinal disturbances, liver dysfunction,
fatigue, hematological abnormalities and flu-like syndrome.
ii. Alitretinoin - Dosage: 30 mg/day. Side effects: Headache, TSH
elevation, teratogenicity
2.Biologics
This class of pharmacological agents are engineered to target specific
mediators of inflammation. Over the past decade, studies have reported the
efficacy of targeted therapy blocking cytokines or mediators which play a role
in AD pathogenesis. [163] According to Deleanu et al., based on mechanism of
action, novel biologic therapies are classified into: anti IL-4 (Dupilumab) and
anti-IL-4/IL-13 agents (Lebrikizumab, Tralokinumab), IgE directed therapy
(Omalizumab), IL-22 blockers (Fezakinumab), anti-IL-12/23 (Ustekinumab),
IL-31 directed therapy (Nemolizumab), thymic stromal lymphopoietin
directed therapy (Tezepelumab), phosphodiesterase inhibitors (Apremilast,
Crisaborole), and JAK inhibitors (Tofacitinib). [163]
a. Rituximab (anti-CD20) is a monoclonal antibody against the protein
CD20, which is primarily found on the surface of immune system B
cells. [157] It reduces the expression of IL-5 and IL-13 by lowering B cell
activation of T-cells. [164] Data on its use in adult patients with severe
AD is limited. [157, 165] Dosage: 500–1000 mg iv (2-cycle infusion
2 weeks apart). Side effects: Headache, fever, nausea, diarrhea,
weakness, flushing, muscle or joint pain, increased risk of infection,
hematological abnormalities
b. Dupilumab, (anti-CD20) is a human monoclonal antibody that targets the
shared α subunit of the IL-4 and IL-13 receptors, effectively blocking Th2
immune response. It is the only biologic drug licensed for treatment of
adult AD. Clinical trials (Phase I-III) demonstrated its efficacy, as well as
good patient and clinical reported outcomes using the SCORAD, IGA,
DLQI and EASI assessment tools and health related quality of life (HRQoL)
measures. [166] Long term use and safety profile still need to be established
from ongoing studies. Dosage: 300 mg every 1–2 weeks. Side effects:
Increased risk of infection, headache, and gastrointestinal disturbances.
c. Others:
i. Interferon-γ and infliximab have been used in severe AD and
there are limited studies on their use. [163–165]
ii. Ustekinumab (anti IL-12, IL-23) 45 mg for patients ≤100 kg;
90 mg for patients >100 kg; at weeks 0 and 4 then every
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12 weeks. Side effects: Headache, myalgia, increased risk of
infection, fatigue, injection site reactions.
iii. Omalizumab (anti-IgE): Dosage: 150–600 mg every 2–4 weeks
Side effects: Increased risk of infection, injection site reactions,
headache
3.Small molecules
Apremilast is a new drug involved in modulation of multiple anti-
inflammatory pathways targeting phosphodiesterase type IV (PDE4) inhibi-
tion. Apremilast downregulates pro-inflammatory transcription of several
cytokines such as TNF-α, IFN-γ, IL-2, IL-5, IL-8 and IL-12. [163] There are
limited studies and data on its use in AD. Dosage: 20–30 mg twice a day. Side
effects: Headache, nausea, diarrhea.
Ultraviolet (UV) therapy [157] has the following functions:
• reduces the number of epidermal nerve fibers and expression of axon guidance
molecules reducing itching,
• upregulates production of FoxP3-positive regulatory T cells thereby reducing
AD severity
• inhibit DNA synthesis hence keratinocyte proliferation,
• suppresses antigen-presenting cells such as Langerhans’ cells,
• induces T lymphocyte apoptosis and
• suppresses anti-inflammatory mediator production
It is often used as second-line treatment for moderate-to-severe AD, resistant/
relapse, chronic and poor topical response cases.
Broadband useful in adult AD: UVB (290–320 nm), narrow-band (NB) UVB
(311–313 nm), excimer laser (308 nm), UVA-1 (340–400 nm), psoralens and UVA
(PUVA), and combined UVA/UVB (280–400 nm).Narrow-band UVB radiation
and medium-dose UVA1 are the most effective and safe for short and long term
treatment.. Medium-dose UVA1 is the only type used in acute flares. Therapy is
usually thrice weekly. Known side effects are nausea, fatigue, headache, itching,
skin burns, blistering, erythema, irregular pigmentation, photodamage, actinic
keratosis, and herpes virus reactivation as well as a higher risk of skin cancer,
premature photoaging and skin cancers.
12. Conclusion
There is a worldwide increase in Adult AD with no standardized guidelines
for its management. This condition greatly affects the quality of life of individuals
and side effects from some of the drugs further limit the long term use of some
forms of treatment. Biologic therapies are likely to change the course of the disease:
decrease exacerbations, increase flare free periods and improve the quality of life.
International guidelines therefore need to be developed based on further research
on systemic immunotherapy options.
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13. Pictures
Atopic Dermatitis in a male child with flexural involvement.
Atopic Dermatitis in a young adult female with involvement of head, neck, and
extensor surfaces of elbows.
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